Cargando…

Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up

BACKGROUND: The purpose of this study was to investigate the ability of Alzheimer’s disease (AD) patients to express intentions and desires, and their decision-making capacity. This study examines the findings from a 6-month follow-up of our previous results in which 30 patients participated. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales: Onofri, Emanuela, Mercuri, Marco, Archer, Trevor, Rapp-Ricciardi, Max, Ricci, Serafino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788358/
https://www.ncbi.nlm.nih.gov/pubmed/27022252
http://dx.doi.org/10.2147/CIA.S94750
_version_ 1782420717474676736
author Onofri, Emanuela
Mercuri, Marco
Archer, Trevor
Rapp-Ricciardi, Max
Ricci, Serafino
author_facet Onofri, Emanuela
Mercuri, Marco
Archer, Trevor
Rapp-Ricciardi, Max
Ricci, Serafino
author_sort Onofri, Emanuela
collection PubMed
description BACKGROUND: The purpose of this study was to investigate the ability of Alzheimer’s disease (AD) patients to express intentions and desires, and their decision-making capacity. This study examines the findings from a 6-month follow-up of our previous results in which 30 patients participated. MATERIALS AND METHODS: The patient’s cognition was examined by conducting the tests of 14 questions and letter-writing ability over a period of 19 days, and it was repeated after 6 months. The difference between these two cognitive measures (PQ1 before–PQ2 before), tested previously and later the writing test, was designated DΔ before. The test was repeated after 6 months, and PQ1 after–PQ2 after was designated DΔ after. RESULTS: Several markedly strong relationships between dysgraphia and other measures of cognitive performance in AD patients were observed. The most aged patients (over 86 years), despite less frequency, maintain the cognitive capacity manifested in the graphic expressions. A document, written by an AD patient presents an honest expression of the patient’s intention if that document is legible, clear, and comprehensive. CONCLUSION: The identification of impairment/deficits in writing and cognition during different phases of AD may facilitate the understanding of disease progression and identify the occasions during which the patient may be considered sufficiently lucid to make decisions.
format Online
Article
Text
id pubmed-4788358
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47883582016-03-28 Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up Onofri, Emanuela Mercuri, Marco Archer, Trevor Rapp-Ricciardi, Max Ricci, Serafino Clin Interv Aging Original Research BACKGROUND: The purpose of this study was to investigate the ability of Alzheimer’s disease (AD) patients to express intentions and desires, and their decision-making capacity. This study examines the findings from a 6-month follow-up of our previous results in which 30 patients participated. MATERIALS AND METHODS: The patient’s cognition was examined by conducting the tests of 14 questions and letter-writing ability over a period of 19 days, and it was repeated after 6 months. The difference between these two cognitive measures (PQ1 before–PQ2 before), tested previously and later the writing test, was designated DΔ before. The test was repeated after 6 months, and PQ1 after–PQ2 after was designated DΔ after. RESULTS: Several markedly strong relationships between dysgraphia and other measures of cognitive performance in AD patients were observed. The most aged patients (over 86 years), despite less frequency, maintain the cognitive capacity manifested in the graphic expressions. A document, written by an AD patient presents an honest expression of the patient’s intention if that document is legible, clear, and comprehensive. CONCLUSION: The identification of impairment/deficits in writing and cognition during different phases of AD may facilitate the understanding of disease progression and identify the occasions during which the patient may be considered sufficiently lucid to make decisions. Dove Medical Press 2016-03-07 /pmc/articles/PMC4788358/ /pubmed/27022252 http://dx.doi.org/10.2147/CIA.S94750 Text en © 2016 Onofri et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Onofri, Emanuela
Mercuri, Marco
Archer, Trevor
Rapp-Ricciardi, Max
Ricci, Serafino
Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title_full Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title_fullStr Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title_full_unstemmed Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title_short Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
title_sort legal medical consideration of alzheimer’s disease patients’ dysgraphia and cognitive dysfunction: a 6 month follow up
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788358/
https://www.ncbi.nlm.nih.gov/pubmed/27022252
http://dx.doi.org/10.2147/CIA.S94750
work_keys_str_mv AT onofriemanuela legalmedicalconsiderationofalzheimersdiseasepatientsdysgraphiaandcognitivedysfunctiona6monthfollowup
AT mercurimarco legalmedicalconsiderationofalzheimersdiseasepatientsdysgraphiaandcognitivedysfunctiona6monthfollowup
AT archertrevor legalmedicalconsiderationofalzheimersdiseasepatientsdysgraphiaandcognitivedysfunctiona6monthfollowup
AT rappricciardimax legalmedicalconsiderationofalzheimersdiseasepatientsdysgraphiaandcognitivedysfunctiona6monthfollowup
AT ricciserafino legalmedicalconsiderationofalzheimersdiseasepatientsdysgraphiaandcognitivedysfunctiona6monthfollowup